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Abstract
Direct injection of murine K-1735 melanoma cells into
the subcutis, lung, or brain of syngeneicmice produces
amelanotic tumors, whereas intravenous injection into
the lateral tail vein or internal carotid artery produces
both amelanotic and melanotic foci in the lung and
the brain respectively. We hypothesized that loss of
adhesion in the circulation may contribute to the
melanogenic phenotypes of cells. To test this, we used
enforced suspension culture of K-1735 cells by con-
sistent rotating culture of K-1735 cells. We found that
the expression of the microphthalmia transcription fac-
tor (MITF) and melanin-stimulating hormone receptor
(MSHR) were upregulated in cells growing in suspen-
sion and were accompanied by inhibitions of AKT and
ERK, which were reversed in cells upon regrowth as
an adherent monolayer. Inhibition of the AKT pathway
was responsible for MITF induction by suspension
culture. Stable expression of constitutively active AKT
significantly repressed the melanogenesis of K-1735
cells injected via circulation. An amelanotic clone of
K-1735 cells was resistant to suspension culture–
induced MITF, although the inhibition of AKT pathway
was intact. Collectively, these data suggest that the in-
hibition of AKT pathway due to loss of adhesion within
the circulation renders a subpopulation of K-1735 cells
to produce melanin.
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Introduction
To establish distant metastases, cancer cells must com-
plete a series of sequential and selective steps, which
includes detachment from the primary tumor, invasion and
intravasation into the circulation (lymphatic or hematoge-
nous), survival in the circulation, extravasation into the
stroma of different organs, production of vasculature, and
growth. The organ microenvironment can profoundly influ-
ence the biologic behavior of tumor cells, including the
production of degradation enzymes, angiogenesis, resis-
tance to chemotherapy, and induction of terminal differenti-
ation [1]. Models of murinemelanomametastasis to the lung
[2] and brain [3,4] have demonstrated multiple tumor–host
interactions during the pathogenesis of metastasis. In these
models, K-1735 murine melanoma cells are injected intrave-
nously into the tail vein to produce lung metastasis, or into the
internal carotid artery to produce brain metastasis in syngeneic
mice. K-1735 tumors growing subcutaneously are amelanotic,
whereas lung and brain metastases are a mixture of both
amelanotic and melanotic lesions [5]. In a previous study, we
found that genes involved in melanogenesis, such as melanin-
stimulating hormone receptor (MSHR) and tyrosinase, were
induced in brain metastases of K-1735 cells, but not in subcu-
taneous K-1735 tumors [6]; these observations suggested that
the organ microenvironment is crucial to the melanogenic
phenotype of K-1735 cells.
Microphthalmia transcription factor (MITF) is central to sig-
naling pathways that control the survival, proliferation, and
differentiation of melanocytes. Genes involved in melanin syn-
thesis, such as tyrosinase [7], tyrosinase-related protein 1 [8],
and MSHR [9], are regulated by MITF. Transcription factors,
such as Pax3, Sox10, CREB, and Lef1, are involved in regu-
lating the mRNA levels of MITF. Signaling pathways, such as
Ras/ERK and PI3 kinase/AKT pathways, are known to be
involved in the phosphorylation MITF, which facilitates the deg-
radation of MITF at the protein level (for a review, see Goding
[10]). Inhibition of AKTor ERK results in the increase of melanin
synthesis in human melanocytes [11]. AKT and ERK are pro-
tein kinases that play an important role in the signaling path-
way by responding to growth factors and other extracellular
stimuli that regulate several cellular functions, including
nutrient metabolism, cell growth, apoptosis, and survival. Many
signaling pathways, including AKT and ERK, are known to be
inhibited by loss of adhesion [12,13], and one of the major
alterations of circulating tumor cells is loss of adherence to
neighboring cells and basal membrane, loss of adhesion, and
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inhibitory effects of AKTand ERK on MITF protein level. This
leads to the hypothesis that melanogenic phenotype may be
activated in circulating melanoma cells.
To test this hypothesis, we compared melanogeneses
by murine K-1735 melanoma cells introduced into organs
by the circulation or by direct injection. The molecular mech-
anisms that regulate melanogenesis in K-1735 melanoma
cells were also explored by culturing the cells in suspension.
Collectively, our data suggest that loss of adhesion of circu-
lating melanoma cells can alter their phenotype.
Materials and Methods
Reagents and Cell Lines
The K-1735 murine melanoma cell line was a gift from
Dr. Margaret L. Kripke (The University of Texas M. D. Ander-
son Cancer Center, Houston, TX) [14]. The amelanotic C2
clone of K-1735 cells and the melanotic C4 clone were iso-
lated as described previously [5]. Stable melanotic B16-BL6
melanoma cells isolated from the B16-F1 line syngeneic to
the C57BL/6 mouse [15] served as positive control. Green
fluorescent protein (GFP)–labeled K-1735 cell was prepared
previously [16]. AKT inhibitor LY294002 and ERK inhibitor
PD98095 were purchased from Sigma (St. Louis, MO).
Polyclonal antibodies against MITF (cat. sc-10999), and
b-actin (cat. sc-1616) and horseradish peroxidase–labeled
secondary antibodies were from Santa Cruz Biotechnology
(Santa Cruz, CA). Polyclonal antibodies against total AKT
(tAKT; cat. 9277), phosphorylated AKT (pAKT; cat. 9271L),
total ERK1/2 (cat. 9102), and phosphorylated ERK1/2 (cat.
9101L) were from Cell Signaling (Beverly, MA). Anti-CD31
antibody (cat. 557355) was from BD Biosciences (San Jose,
CA). The transfection reagent Fugen6 was from Roche
(Basel, Switzerland). Geneticin was purchased from Invi-
trogen (Carlsbad, CA).
Animals
Specific pathogen-free mice of the inbred strains C3H/
HeN were purchased from the Animal Production Area of the
National Cancer Institute-Frederick Cancer Research Facility
(Frederick, MD). Animals were maintained in facilities ap-
proved by the American Association for Accreditation of
Laboratory Animal Care, in accordance with current regula-
tions and standards of the US Department of Agriculture, the
US Department of Health and Human Services, and the
National Institutes of Health.
Tumor Cell Injections
To produce tumors, K-1735 cells were harvested from
subconfluent adherent cultures by a short treatment with
0.25% trypsin and 0.02% EDTA. Trypsinization was stopped
with a medium containing 10% fetal bovine serum, and the
cells were washed once in serum-free medium and then
suspended in Hank’s balanced salt solution. Only single-cell
suspensions with > 90% viability were used for injections.
Tumor cells (1.0  105 in 100 ml) were injected into the
subcutis, tail vein, or internal carotid artery, as described
previously [3]. For direct intraorgan injection, cells (1.0 
105 in 50 ml) were injected into the left lung or into the brain
(through the right parietal bone) using a 1-ml syringe with a
30-gauge needle. Tissues from animals (n = 5 in each group)
were collected 3 weeks after the injections. In parallel, to
track the changes of pAKT after injection through the circu-
lation, green fluorescence–labeled K-1735 cells were used
and tissues were collected and immediately frozen with
liquid nitrogen at 6 hours after injection for immunohisto-
chemical staining of pAKTand CD31.
Immunohistochemical Staining for pAKT and CD31
on Sequential Sections
Sequential frozen sections (15 mm thickness) of tissues
containing GFP-labeled K-1735 cells were made with Cryo-
stat LEICA CM3050 (Bannockburn, IL). Slides were then
air-dried, fixed in cold acetone and ethanol for 2 minutes
each, then air-dried before staining. The slides were blocked
with a blocking solution (3% bovine serum albumin in PBS
containing 0.1%NP-40) for 1 hour at room temperature. After
blocking, slides were incubated with a primary antibody
against pAKT (1:100) that was diluted with blocking buffer
for 3 hours at room temperature. After washing thrice in PBS
(2 minutes each), the slides were incubated for 1 hour at
room temperature with a secondary antibody conjugated
with red fluorescence (Alexa 594). After three washes with
PBS (5 minutes each), the slides were stained with fluores-
cent nuclear staining dye (Hoechst 33342, Molecular Probes,
Eugene, OR) and mounted with antifading medium. Stained
sections were examined under a Nikon Microphot-FX (Mel-
ville, NY) microscope equipped with a three-chip charge-
coupled device color video camera (Model DXC990; Sony
Corp., Tokyo, Japan). After photography, the pictured areas
were marked on the slides. Sequential sections of pAKT-
stained samples were then stained with a primary antibody
against CD31 for vascular endothelial cells. Red fluores-
cence secondary antibody (Alexa 594) was used to visualize
CD31 signal, as described above.
Cell Culture
For adherent cultures, K-1735 cells (5.0  106) were
incubated in 100-mm plastic dishes (Corning, Corning, NY)
in Dulbecco’s modified Eagle’s medium supplemented with
10% fetal bovine serum, sodium pyruvate, nonessential
amino acids, L-glutamine, and two-fold vitamin solution
(Gibco, Grand Island, NY) and in 5% CO2–95% air at
37jC. For enforced suspension cultures, the cells were har-
vested from adherent cultures (as described in the Immuno-
histochemical Staining for pAKT and CD31 on Sequential
Sections section), incubated in 100-mm plastic dishes, and
placed on a consistent rotator (120 rpm) in a CO2 incubator.
To examine the properties of cells growing in suspension and
then as adherent monolayers, K-1735 cells were grown for
6 hours in a dish placed on a horizontal rotator, and then the
dish was removed from the rotator and the cells were allowed
to grow as adherent monolayers for another 6 hours. To
inhibit the activation of AKT or ERK, adherent cells that
had reached 80% confluency were treated with LY294002
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(10 nM) or PD98095 (25 nM) for 12 hours. Control cells were
treated with a medium containing the same volume of the
vehicle, dimethyl sulfoxide. There were triplicates of cell
culture in each group of experiments.
Transfection of K-1735 Cells with Constitutively Active AKT
Plasmids of constitutively active AKT1 (Myc-his tagged
myr-AKT1) and control vector were purchased from Upstate
Biotechnology (Lake Placid, NY). myr-AKT1 and control
plasmids were transfected into cells with the transfection
reagent, Fugen6. Stable clones with myr-AKT1 or control
vector were established by culturing transfected cells for
3 weeks in a medium with 1 mg/ml geneticin. Clones were
selected by Western blot analysis, with anti-myc antibody re-
cognizing the myc tag of myr-AKT1.
Histopathological Analysis
Tissues with tumors were collected from anesthetized
mice, placed into Bouin’s fluid, embedded in paraffin, and
sectioned for staining with hematoxylin and eosin (H&E) for
morphologic evaluation. Photographs of the organs (with
tumors) were taken before and after fixation in Bouin’s fluid.
Northern Blot and Western Blot Analyses
The expression level of MSHR mRNA was measured by
Northern blot analysis, as described previously [4]. Western
blot analysis was carried out according to protocols de-
scribed previously [17]. Briefly, whole cell lysates were pre-
pared by incubating K-1735 cells for 10 minutes at 0jC in a
lysis buffer (50 mM HEPES, pH 7.4, 150 mM NaCl, 0.1%
Triton X-100, 1.5 mM MgCl2, 1 mM EDTA, and 1 mM phenyl-
methylsulfonyl fluoride) and by centrifuging at 900g for
10 minutes, and then the supernatant was collected. To
isolate membranes, the cells in a lysis buffer were disrupted
by sonication (5 seconds  5 bursts) at 0jC using a Sonic
Dismambrator (Fisher Scientific, Pittsburgh, PA). The ho-
mogenate was centrifuged (900g for 10 minutes) to remove
unbroken cells and nuclei, and the supernatant was centri-
fuged for 1 hour at 100,000g. The pellet containing mem-
branes was suspended at a concentration equivalent to 1.0
106 cells/ml in the same buffer. Equal amounts of proteins
were separated by 7% sodium dodecyl sulfate–polyacryl-
amide gel electrophoresis and then transblotted to nitro-
cellulose, blocked with 5% nonfat dry milk for 2 hours at
room temperature, and incubated overnight with primary
antibodies. Immunoreactive signals were visualized by en-
hanced chemiluminescence.
Quantification Blot Signals
The density of individual bands on each blot was quanti-
fied with a Personal Densitometer SI (Molecular Dynamics,
Sunnyvale, CA). The band density of target molecules was
normalized against the loading control band, and its fold
difference, compared with the band of a control sample,
was calculated by the formula: Band density of experiment/
Band density of control. The fold difference that was either
> 1.5 or < 0.5 was considered as significant.
Results
Intravascular Injections Produce Both Melanotic
and Amelanotic Tumors
In C3H/Hen mice that received direct injections of K-1735
cells into the subcutis, lung, or brain, none of the resulting
tumors was melanotic (Figure 1). In contrast, tumor foci
(experimental metastases) produced in the lung subsequent
to intravenous injection into the lateral tail vein were either
melanotic or amelanotic. Tumor lesions produced in the brain
subsequent to injection into the internal carotid artery were
mostly melanotic, with some amelanotic regions.
Inhibition of AKT Activity in Circulating Tumor Cells
Tumor cells directly injected into tissues are likely to
immediately contact the tissue stroma, whereas tumor cells
injected into the circulation have a period time of suspension
in the blood. Loss of adhesion usually leads to inhibition of
AKT [18], and inhibition of AKT results in increased melanin
synthesis [11]. We tested whether the AKT pathway was
inhibited in GFP-labeled K-1735 cells that were injected into
either the subcutis, the lateral tail vein, or the internal carotid
artery of the same mouse (n = 5). Tissues were harvested at
6 hours after injection by immediately freezing with liquid
nitrogen. As shown in Figure 2, tumor cells in the subcutis
express pAKT, whereas tumor cells within the vessels do not.
Melanogenesis-Related Genes Are Induced by Culturing in
Suspension and Are Accompanied by Inhibition of the AKT
and ERK Pathways
We test the possibility of loss adhesion contributing to
melanin synthesis. We culture K-1735 cells (adherent in na-
ture) in suspension by an enforced suspension culture using
a consistent rotator. The expression of MITF and MSHR and
the activation of AKTand ERK pathways were compared be-
tween cells growing in suspension and cells growing as
adherent monolayers. Western blot analysis showed that,
compared with adherence, growth in suspension was asso-
ciated with the upregulation of MITF and the inhibition of the
AKT and ERK pathways. Other than G1 arrest, the enforced
suspension culture did not lead to cell death (data not shown),
which is probably due to the upregulation of Bcl-2 by sus-
pension culture (Figure 3A). Northern blot analysis revealed
that the mRNA of MSHR, one of the MITF target genes for
melanogenesis, was also upregulated in cells growing in
suspension (Figure 3B).
AKT Inhibition Is Responsible for MITF Induction
To test the specificity of AKT and ERK pathway in the
upregulation of MITF, we treated adherent K-1735 cells for
12 hours with the AKT inhibitor LY294002 or the ERK inhibitor
PD98095. AKT inhibition induced the expression of MITF
(Figure 4A), whereas ERK inhibition did not (Figure 4B). The
inhibition of AKTactivation and the induction of MITF in sus-
pended cells were reversed once the suspended cells were
allowed to readhere and grow for 6 hours (Figure 5).
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K-1735 Cells That Express Constitutively Active AKT
Do Not Produce Melanotic Lesions
To determine whether the inhibition of AKT leads to the
induction of melanogenesis in K-1735 cells growing in vivo,
we developed K-1735 cells to express constitutively active
AKT (myc-tagged myr-AKT1). As shown in Figure 6A, the
expression of myc-tagged myr-cAKT1 in stably transfected
cells was confirmed by the presence of myc tag recognized
Figure 2. Inhibition of AKT in circulating tumor cells. Sequential frozen sections of the brain (K-1735 cells injected through the internal carotid artery), lung (K-1735
cells injected intravenously through the tail vein), and the subcutis (subcutaneously) containing GFP-labeled K-1735 cells (arrowheads, green) were stained for
pAKT (arrowhead, red), CD31 (arrow, red), and cell nuclei (Hoechst, blue). Note that the K-1735 melanoma cells within the vasculature are negative for pAKT and
that the tumor cells in the subcutis are positive. Bar = 50 m.
Figure 1. Induction of melanogenesis in circulating K-1735 cells. Tumors produced by K-1735 cells injected directly into the subcutis subcutaneously (s.c.), lung
intrapleural (i.p.), or brain intracerebroventricularly (i.c.) are amelanotic. In contrast, K-1735 cells introduced into the lung by injection into the lateral tail vein
intravenously (i.v.), or into the brain by injection into the internal carotid artery (i.c.a.) produce melanotic lesions (bar = 300 mm). The heterogeneity of
melanogenesis in brain lesions is shown by the H&E-stained ICA section. Bar = 20 m.
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by anti-myc antibody, and the membrane-bound pAKT was
detected in the membrane fraction of cells. K-1735 cells
transfected with a control vector had significantly inhibited
membrane AKT phosphorylation after 6 hours in suspension
culture. In contrast, myr-cAKT1–expressing cells are resis-
tant to the inhibition of membrane-bound AKT phosphoryla-
tion by enforced suspension culture. b-Actin from an equal
volume of cytosolic fraction of each sample was used as
loading control.
K-1735 cells transfected with myr-AKT or vector control
were injected intravenously into the lateral tail vein. Tumor
foci in the lung of C3H/HeN mice produced by control cells
were mostly pigmented, whereas foci produced by the
cells transfected with myr-AKT1 were not (Figure 6B). Intra-
venous injection of these cells into the internal carotid ar-
tery produced tumor lesions in the brain of syngeneic mice
(Figure 6C). Histologic examination (Figure 6D) revealed
that control cells produced melanotic lesions, whereas the
cells that expressed myr-AKT did not.
Growth in the Suspension of Amelanotic K-1735 Clone
Inhibits AKT Phosphorylation But Does Not Upregulate
MITF Expression
Because not all the K-1735 cells injected intravenously
produce melanotic lung metastases, we examined the prop-
erties of two clones isolated previously in our laboratory [5].
Clone 2 is highly metastatic and amelanotic, and clone 4 is
highly metastatic and melanotic. Clones 2 and 4 cells were
grown in suspension culture. As shown in Figure 7, the phos-
phorylation of AKTwas inhibited in both clones 2 and 4 cells;
however, MITF expression was upregulated only in clone 4
(melanotic) cells grown in suspension.
Discussion
The interaction of cancer cells with factors unique to specific
organ microenvironments determines the outcome of cancer
metastasis [19]. Whether the circulation per se alters the
phenotype of metastatic cells remained unclear. Tumor cells
growing in organs are closely attached to each other and to
host cells, and adherent culture method has been widely
used for in vitro studies. Circulating tumor cells are more
akin to cells growing in suspension, at least on one aspect
(loss of adhesion). The loss of adhesion of circulating tumor
cells can lead to multiple changes, such as the inhibition of
AKTand ERK phosphorylation, thereby leading to cell death
(so-called anoikis) [20]. Indeed, the majority of circulating
tumor cells rapidly die [21,22], and circulating cells that
are resistant to anoikis present with activated AKT, ERK, or
both [23,24]. In contrast, in our study, the expression levels
of pAKT and ERK in K-1735 cells growing in suspension
culture were reduced, but the cells did not undergo anoikis
(data not shown); indeed, the level of the antiapoptotic
molecule Bcl-2 was upregulated. That Bcl-2 upregulation
was accompanied by the inhibition of AKT and ERK activity
is actually expected for melanoma cells becauseMITF, which
is unique to melanocytes [10,25], can induce Bcl-2 expres-
sion [26]. Both AKT and ERK pathways are involved in the
regulation of MITF [27,28]. The basal level of MITF in ad-
herent K-1735 cells is barely detectable, which explains their
amelanotic phenotype. Because the basal level of MITF in
Figure 3. Suspension culture upregulation of melanogenesis-related genes
inhibits the AKT and ERK pathways. (A) Western blot analysis of pAKT, tAKT,
phosphorylated ERK (pERK1/2), total ERK (tERK1/2), and MITF. K-1735
cells growing in suspension culture (Sp) for 3 hours exhibit upregulated MITF
expression and inhibited pAKT and pERK1/2 expression. These changes are
not found in adherent K-1735 cells (Ad). The target gene of MITF, Bcl-2, was
also upregulated accordingly. Actin was used as loading control. Cell lysate
from B16-F10 melanoma cells served as positive control. (B) Northern blot
analysis of MSHR mRNA expression in K-1735 cells grown in suspension or
in adherent monolayers. K-1735 cells growing in suspension culture exhibit
upregulated MSHR expression. Tubulin was used as loading control. Total
mRNA from B16-F10 melanoma cells served as positive control.
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K-1735 cells is very low, the induction of MITF by the inhibi-
tion of AKT, but not ERK, suggests that the repression of
MITF by AKT is likely to be on the transcription level and that
the repression of MITF by ERK is likely to be on the protein
level. Indeed, it has been reported that the activation of ERK
facilitates the degradation of MITF through the ubiquitin-
mediated proteasome pathway [29].
We found that intravenous injection of K-1735 cells into
the lateral tail vein leads to the production ofmelanoticmetas-
tases in the lung and that intravenous injection of K-1735
cells into the internal carotid artery leads to the production
of melanotic lesions in the brain. The lung or brain micro-
environment per se cannot be the regulators of melano-
genesis in these cells because the direct injection of K-1735
cells into the organs did not result in melanotic lesions. How-
ever, these organ microenvironments must contribute to the
stabilization of melanogenesis in cells that have extra-
vasated from the circulation and have proliferated in the
organ parenchyma. This conclusion is based on the finding
that the inhibition of AKT in cells within the vasculature and
the induction of MITF in K-1735 cells growing in suspension
culture were reversed once these cells were allowed to
grow as adherent monolayers. The heterogeneity of the pa-
rental K-1735 cells for response to growth in suspension
correlates with the heterogeneous melanogenic phenotype
in vivo. Specifically, stable amelanotic cells (e.g., clone 2
cells) have defects in signaling that are associated with
AKT inhibition and MITF induction.
The relevance of circulating tumor cells to the prognosis
and therapy of cancer is gaining increased attention. A large
body of research suggests that circulating tumor cells can be
studied to monitor the efficacy of therapy, but little is known
about the phenotypic variability of circulating cells and how
the circulatory system per se affects these phenotypes
[30,31]. Because all neoplasms are biologically heteroge-
neous [32,33], some characteristics associated with circulat-
ing cells could be associated with metastatic subpopulations
[34]. Our present data suggest that phenotypes unique to
circulating cells may also be due to the influence of the
Figure 5. Suspension culture leads to reversible upregulation of melano-
genesis-related genes. Western blot analysis shows that the inhibition of
pAKT and the upregulation of MITF in suspended cells can be reversed by
allowing the suspended cells to readhere for 6 hours. Actin was used as
loading control.
Figure 4. Western blot analysis of MITF expression in adherent K-1735 cells treated with AKT inhibitor LY294002 or ERK inhibitor and PD98095. (A) The AKT
inhibitor LY294002 inhibited AKT phosphorylation and induced MITF expression without affecting levels of either tAKT or phosphorylated ERK1/2 (pERK1/2). (B)
The ERK inhibitor PD98095 did not induce MITF expression, but significantly inhibited pERK1/2. Actin was used as loading control.
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circulatory system. In other words, the reality of the interac-
tion between the ‘‘seed and the soil’’ [35] should be extended
to tumor cells in the circulation.
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